Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFβ1 Gene

International Journal of Radiation Oncology Biology Physics

Volumn 85, Issue 2, 2013, Pages 393-399

  De Langhe, Sofie ^a   De Ruyck, Kim ^a   Ost, Piet ^b   Fonteyne, Valérie ^b   Werbrouck, Joke ^a   De Meerleer, Gert ^b   De Neve, Wilfried ^b   Thierens, Hubert ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE TOXICITY; DOSE-VOLUME PARAMETERS; DOSIMETRIC PARAMETER; GENETIC MARKERS; INTENSITY-MODULATED RADIATION THERAPY; PRE-TREATMENT; PROSTATE CANCERS; QUALITY OF LIFE; RADIATION-INDUCED; RADIATION-INDUCED DAMAGES; RADICAL PROSTATECTOMY;

DISEASES; DOSIMETERS; DOSIMETRY; GENES; PATIENT MONITORING; RADIATION; RADIOTHERAPY; TOXICITY; UROLOGY;

PHYSICAL THERAPY;

GONADORELIN DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE RADIATION INDUCED NOCTURIA; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CODON; DOSIMETRY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; NOCTURIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION INJURY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; TRANSURETHRAL RESECTION;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; CODON; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; NOCTURIA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84872176603     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.02.061     Document Type: Article

References (20)

1. B.S. Teh, W.Y. Mai, and B.M. Uhl Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis Int J Radiat Oncol Biol Phys 49 2001 705 712
2. V. Fonteyne, G. Villeirs, and N. Lumen Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer Radiother Oncol 92 2009 42 47
3. G. De Meerleer, L. Vakaet, and S. Meersschout Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients Int J Radiat Oncol Biol Phys 60 2004 777 787
4. D.P. Dearnaley, V.S. Khoo, and A.R. Norman Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial Lancet 353 1999 267 272
5. I.M. Lips, H. Dehnad, and C.H. van Gils High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients Radiat Oncol 3 2008 15
6. S.T.K. Peeters, W.D. Heemsbergen, and W.L.J. Van Putten Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy Int J Radiat Oncol Biol Phys 61 2005 1019 1034
7. B.A. Jereczek-Fossa, D. Zerini, and C. Fodor Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-dimensional conformal external beam radiotherapy Int J Radiat Oncol Biol Phys 78 2010 26 34
8. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
9. V. Kupelian, J.T. Wei, and M.P. O;Leary Nocturia and quality of life: results from the Boston area community health survey Eur Urol 61 2012 78 84
10. P.E.V. Van Kerrebroeck, R. Dmochowski, and M.P. FitzGerald Nocturia research: current status and future perspectives Neurourol Urodynam 29 2010 623 628
11. M.J. Zelefsky, R.X. Ginor, and Z. Fuks Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 45 1999 567 570
12. J.J. Nuyttens, S. Milito, and P.F. Rust Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer Radiother Oncol 64 2002 209 214
13. B.S. Rosenstein Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy Pharmacogenomics 12 2011 267 275
14. H.P. Rodemann, and B.G. Wouters Molecular and translational radiation biology/oncology: what's up? Radiother Oncol 99 2011 257 261
15. M.A. Schirmer, J. Brockmoller, and M. Rave-Frank A putatively functional haplotype in the gene encoding transforming growth factor beta-1 as a potential biomarker for radiosensitivity Int J Radiat Oncol Biol Phys 79 2011 866 874
16. T. Suga, A. Ishikawa, and M. Kohda Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients Int J Radiat Oncol Biol Phys 69 2007 685 693
17. L. Zhang, M. Yang, and N. Bi Association of TGF-beta 1 and XPD polymorphisms with severe acute radiation-induced esophageal toxicity in locally advanced lung cancer patients treated with radiotherapy Radiother Oncol 97 2010 19 25
18. P. Ost, B. De Troyer, and V. Fonteyne A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 80 2011 1316 1322
19. K. De Ruyck, M. Van Eijkeren, and K. Claes TGF beta 1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors Int J Radiat Oncol Biol Phys 65 2006 1240 1248
20. C. West, B.S. Rosenstein, and J. Alsner Establishment of a radiogenomics consortium Int J Radiat Oncol Biol Phys 76 2010 1295 1296